In the world of penny stocks, companies that produce consistent earnings stand out. One such company is Zhone Technologies, Inc. (NASDAQ: ZHNE).
On Jan. 22, the Oakland-Calif–based maker of networking equipment (NASDAQ: ZHNE) reported net income for the December-ended quarter of 4 cents a share, a penny lower than earnings in the preceding quarter.
Zhone reported revenue of $32.3 million, which was 14.1% higher than the same quarter a year ago. For fiscal 2013, Zhone Technologies generated net income of 14 cents a share on $122.25-million revenue. Many analysts covering the company had expected Zhone to generate a net income of 15 cents a share on its $122.47 million revenue.
However, the company’s CEO was not unhappy with the results.
"When we entered 2013, our primary financial goal was to generate profitability for the year as a whole,” said Zhone Technologies CEO Mory Ejabat said in a written statement. "Having achieved both top line growth and profitability, we enter 2014 with two primary financial objectives: generating continued revenue growth and improving profitability," he added.
On Jan. 27, ZHNE share price closed at $4.57 cents, up 22 cents from the share price of $4.35 the previous day.
Find out what could be the best investor’s move when it comes to ZHNE by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Bad news hurts
Cleveland BioLabs Inc. (NASDAQ:CBLI) stock volume soared Jan. 27 with 1,389,311 shares changing hands, which is nearly four times its three-month average of 296,847 shares.
The flurry of sales could possibly be tied to some recent negative news regarding the drug discovery and development company based in Buffalo, New York.
Last week, two law firms announced that they were investigating whether certain alleged statements Cleveland BioLabs made regarding the company’s Jan. 14 public offering were "possible violations of federal securities laws."
So far, neither law firm has yet to bring a lawsuit against the company. Their investigations are based on allegations that may or may not have merit. So far, Cleveland BioLabs has not responded publicly to the news of the investigations.
In addition to this, Cleveland BioLabs’ Jan. 24th announcement that the Biomedical Advanced Research and Development Authority ("BARDA") had terminated negotiations related to the Company's proposal for further development of Entolimod as a medical radiation countermeasure. This also was not good news.
Nonetheless, of the two analysts that cover Cleveland BioLabs, one recommends a "strong buy," of its stock, while the other recommends a "hold."
On Jan. 27, CBLI share price closed at 68 cents, down 1 cent from the share price of 69 cents the previous day.
Find out what could be the best investor’s move when it comes to CBLI by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Positioned to buy more shipping vessels
On Jan 27, FreeSeas Inc. (NASDAQ: FREE), a transporter of dry-bulk cargoes, share price closed at $1.86 up 6 cents from $1.80 share price the previous day.
Some analysts believe the Athens Greece-based FreeSeas stock price will continue to grow because it will soon be buying more vessels using the $8.5-million infusion it received in December to expand its fleet.
"The company shall now be in a financial position to finance the dry-dockings of its fleet enabling the return to operation of the vessels at a very opportune time, as the market recovery gathers pace," FreeSeas’ CEO Ion G. Varouxakis said in a Dec. 30, 2013 written statement.
"This injection shall also position the company for the acquisition of vessels that can immediately produce income. We look into the coming year with great expectations," he added.
Find out what could be the best investor’s move when it comes to FREE by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.sixfigurestockpicks.com
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.